Sorrento Therapeutics, Inc. (SRNE)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 110.87 Million USD | -44.82% |
| 2021 | 200.91 Million USD | 77.91% |
| 2020 | 112.92 Million USD | -57.9% |
| 2019 | 268.26 Million USD | 312.99% |
| 2018 | 64.95 Million USD | 526.84% |
| 2017 | -15.21 Million USD | 56.62% |
| 2016 | -35.08 Million USD | -17.69% |
| 2015 | -29.8 Million USD | 50.12% |
| 2014 | -59.75 Million USD | -122.46% |
| 2013 | -26.86 Million USD | -427.6% |
| 2012 | -5.09 Million USD | -46.87% |
| 2011 | -3.46 Million USD | 34.32% |
| 2010 | -5.27 Million USD | -53.87% |
| 2009 | -3.42 Million USD | -801.52% |
| 2008 | -380.46 Thousand USD | -1638.93% |
| 2007 | -21.87 Thousand USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 9537.00 USD | 0.0% |
| 2003 | 9537.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q1 | 131.89 Million USD | 18.96% |
| 2023 Q2 | 137.85 Million USD | 4.52% |
| 2022 Q4 | 110.87 Million USD | 13.68% |
| 2022 Q1 | 136.97 Million USD | -31.82% |
| 2022 FY | 110.87 Million USD | -44.82% |
| 2022 Q3 | 97.52 Million USD | -27.36% |
| 2022 Q2 | 134.26 Million USD | -1.98% |
| 2021 Q4 | 200.91 Million USD | 23.4% |
| 2021 Q1 | 113.08 Million USD | 0.14% |
| 2021 Q2 | 87.45 Million USD | -22.67% |
| 2021 Q3 | 162.82 Million USD | 86.18% |
| 2021 FY | 200.91 Million USD | 77.91% |
| 2020 Q4 | 112.92 Million USD | -23.56% |
| 2020 Q3 | 147.73 Million USD | -24.8% |
| 2020 Q2 | 196.45 Million USD | -15.73% |
| 2020 Q1 | 233.11 Million USD | -13.1% |
| 2020 FY | 112.92 Million USD | -57.9% |
| 2019 FY | 268.26 Million USD | 312.99% |
| 2019 Q2 | 248.9 Million USD | 26.01% |
| 2019 Q4 | 268.26 Million USD | -4.87% |
| 2019 Q1 | 197.53 Million USD | 164.97% |
| 2019 Q3 | 281.99 Million USD | 13.29% |
| 2018 Q2 | -29.07 Million USD | -69.44% |
| 2018 Q4 | 74.54 Million USD | 94.52% |
| 2018 FY | 64.95 Million USD | 526.84% |
| 2018 Q1 | -17.15 Million USD | -12.74% |
| 2018 Q3 | 38.32 Million USD | 231.84% |
| 2017 FY | -15.21 Million USD | 56.62% |
| 2017 Q1 | -7.83 Million USD | 77.66% |
| 2017 Q2 | -27.14 Million USD | -246.35% |
| 2017 Q3 | -11.34 Million USD | 58.21% |
| 2017 Q4 | -15.21 Million USD | -34.19% |
| 2016 FY | -35.08 Million USD | -17.69% |
| 2016 Q1 | -12.75 Million USD | 57.22% |
| 2016 Q2 | -91.31 Million USD | -616.11% |
| 2016 Q3 | -60.83 Million USD | 33.38% |
| 2016 Q4 | -35.08 Million USD | 42.33% |
| 2015 FY | -29.8 Million USD | 50.12% |
| 2015 Q2 | -40.21 Million USD | 16.75% |
| 2015 Q1 | -48.3 Million USD | 19.16% |
| 2015 Q3 | -48.69 Million USD | -21.09% |
| 2015 Q4 | -29.8 Million USD | 38.79% |
| 2014 Q2 | -38.1 Million USD | -112.33% |
| 2014 Q3 | -32.16 Million USD | 15.58% |
| 2014 FY | -59.75 Million USD | -122.46% |
| 2014 Q4 | -59.75 Million USD | -85.76% |
| 2014 Q1 | -17.94 Million USD | 33.19% |
| 2013 Q4 | -26.86 Million USD | -1533.55% |
| 2013 FY | -26.86 Million USD | -427.6% |
| 2013 Q2 | -4.92 Million USD | 43.77% |
| 2013 Q1 | -8.76 Million USD | -72.11% |
| 2013 Q3 | -1.64 Million USD | 66.63% |
| 2012 Q2 | -7.62 Million USD | -212.07% |
| 2012 Q4 | -5.09 Million USD | 21.01% |
| 2012 Q3 | -6.44 Million USD | 15.47% |
| 2012 FY | -5.09 Million USD | -46.87% |
| 2012 Q1 | -2.44 Million USD | 29.51% |
| 2011 Q1 | -4.71 Million USD | 10.68% |
| 2011 Q4 | -3.46 Million USD | -52.68% |
| 2011 Q3 | -2.27 Million USD | 22.31% |
| 2011 Q2 | -2.92 Million USD | 38.01% |
| 2011 FY | -3.46 Million USD | 34.32% |
| 2010 Q3 | -1.96 Million USD | 9.75% |
| 2010 FY | -5.27 Million USD | -53.87% |
| 2010 Q2 | -2.17 Million USD | 18.79% |
| 2010 Q4 | -5.27 Million USD | -168.48% |
| 2010 Q1 | -2.68 Million USD | 21.81% |
| 2009 FY | -3.42 Million USD | -801.52% |
| 2009 Q1 | -364.53 Thousand USD | 4.18% |
| 2009 Q2 | -291.67 Thousand USD | 19.99% |
| 2009 Q3 | -3.95 Million USD | -1255.89% |
| 2009 Q4 | -3.42 Million USD | 13.27% |
| 2008 Q1 | -17.13 Thousand USD | 21.67% |
| 2008 FY | -380.46 Thousand USD | -1638.93% |
| 2008 Q4 | -380.46 Thousand USD | 8.69% |
| 2008 Q3 | -416.65 Thousand USD | -2004.37% |
| 2008 Q2 | 21.87 Thousand USD | 227.66% |
| 2007 Q1 | -75.45 Thousand USD | 0.0% |
| 2007 Q3 | -30.01 Thousand USD | 29.8% |
| 2007 Q4 | -21.87 Thousand USD | 27.1% |
| 2007 Q2 | -42.75 Thousand USD | 43.34% |
| 2007 FY | -21.87 Thousand USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q1 | 9537.00 USD | 0.0% |
| 2005 Q4 | - USD | -100.0% |
| 2005 Q3 | 9537.00 USD | 0.0% |
| 2005 Q2 | 9537.00 USD | 0.0% |
| 2005 FY | - USD | -100.0% |
| 2004 Q1 | 9537.00 USD | 0.0% |
| 2004 Q3 | 9537.00 USD | 0.0% |
| 2004 FY | 9537.00 USD | 0.0% |
| 2004 Q2 | 9537.00 USD | 0.0% |
| 2004 Q4 | 9537.00 USD | 0.0% |
| 2003 FY | 9537.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 298.194% |
| Alkermes plc | -166.73 Million USD | 166.493% |
| Agenus Inc. | 274.13 Million USD | 59.557% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 94.071% |
| Aptorum Group Limited | 1.35 Million USD | -8069.951% |
| Ardelyx, Inc. | 34.51 Million USD | -221.251% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -2490.421% |
| Bicycle Therapeutics plc | -481.46 Million USD | 123.028% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | -206.584% |
| ChromaDex Corporation | -24.04 Million USD | 561.036% |
| Chimerix, Inc. | -25.51 Million USD | 534.495% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -1491.114% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 568.26% |
| CRISPR Therapeutics AG | -150.84 Million USD | 173.499% |
| Precision BioSciences, Inc. | -85.41 Million USD | 229.809% |
| Dyadic International, Inc. | -6.37 Million USD | 1838.292% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 795.851% |
| Fortress Biotech, Inc. | 7.66 Million USD | -1346.445% |
| Lantern Pharma Inc. | -21.7 Million USD | 610.844% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 200.301% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 1397.761% |
| Incyte Corporation | -3.17 Billion USD | 103.492% |
| IO Biotech, Inc. | -140.69 Million USD | 178.799% |
| Jaguar Health, Inc. | 29.39 Million USD | -277.224% |
| Novavax, Inc. | -298.29 Million USD | 137.168% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -1977.384% |
| Opthea Limited | 28.15 Million USD | -293.75% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 760.373% |
| ContextLogic Inc. | -232 Million USD | 147.789% |
| MiMedx Group, Inc. | -33.9 Million USD | 427.041% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -987.494% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 4885.011% |
| NextCure, Inc. | -6.47 Million USD | 1811.749% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 319.54% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 1838.047% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -811.515% |
| Vaxcyte, Inc. | -368.22 Million USD | 130.109% |
| PDS Biotechnology Corporation | -32.7 Million USD | 438.96% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -541.683% |
| Pharming Group N.V. | 109.8 Million USD | -0.971% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 737.33% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 163.271% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 698.655% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 698.655% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 1661.549% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 1991.98% |
| Acelyrin, Inc. | -216.9 Million USD | 151.115% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 2076.198% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 6530.974% |
| Summit Therapeutics Inc. | 34.67 Million USD | -219.75% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 1729.722% |
| Senti Biosciences, Inc. | 1.74 Million USD | -6271.839% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 160.057% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 243.149% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 1928.934% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -111026.703% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -17554.459% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 194.723% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 165.903% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 1559.584% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 185.87% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -1508.071% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 145.745% |
| Immix Biopharma, Inc. | -17.5 Million USD | 733.189% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 135.008% |
| MEI Pharma, Inc. | -3.7 Million USD | 3092.443% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -786.18% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 31.453% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | -298.913% |
| Fortress Biotech, Inc. | 7.66 Million USD | -1346.445% |
| Precigen, Inc. | -481 Thousand USD | 23149.896% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -687.373% |
| AlloVir, Inc. | -62.69 Million USD | 276.849% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 299.356% |
| Fate Therapeutics, Inc. | 61.66 Million USD | -79.791% |
| ImmuCell Corporation | 10.99 Million USD | -908.775% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 171.925% |
| Onconetix, Inc. | 5.33 Million USD | -1979.552% |
| PureTech Health plc | -167.19 Million USD | 166.311% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 463.986% |
| Elevation Oncology, Inc. | -19.11 Million USD | 679.925% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 2358.505% |
| Seer, Inc. | -4.24 Million USD | 2714.858% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 561.247% |
| Innoviva, Inc. | 255.56 Million USD | 56.617% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 298.464% |
| ESSA Pharma Inc. | -33.62 Million USD | 429.758% |
| GlycoMimetics, Inc. | -40.98 Million USD | 370.517% |
| GT Biopharma, Inc. | -1.02 Million USD | 10958.962% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 263.566% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | -80.992% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 182.69% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 900.159% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 484.005% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 147271.264% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 459.244% |
| Aptose Biosciences Inc. | -8.19 Million USD | 1452.922% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 3643.284% |
| Soligenix, Inc. | -4.95 Million USD | 2339.076% |
| Century Therapeutics, Inc. | 847 Thousand USD | -12989.728% |
| Kura Oncology, Inc. | -20.11 Million USD | 651.099% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 370.904% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 1420.195% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -5986.09% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 3567.939% |
| Autolus Therapeutics plc | -186.59 Million USD | 159.416% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 324.87% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 140.2% |
| Eterna Therapeutics Inc. | 34.26 Million USD | -223.538% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 32.548% |
| GRI Bio, Inc. | -1.79 Million USD | 6280.045% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 1334.214% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 433.373% |
| IGM Biosciences, Inc. | -72.6 Million USD | 252.701% |
| INmune Bio, Inc. | -25.41 Million USD | 536.307% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 26.552% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 318.855% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 782.303% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 3943.08% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | -191.648% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 369.2% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -247.718% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 70.666% |
| Verastem, Inc. | -37.27 Million USD | 397.414% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 1321.977% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 313.779% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 832.54% |
| Histogen Inc. | -7.48 Million USD | 1580.833% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 613.125% |
| Surrozen, Inc. | -32.66 Million USD | 439.426% |
| Organovo Holdings, Inc. | -1.5 Million USD | 7457.001% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 2737.571% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -484.751% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -4138.15% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -2567.709% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 1422.849% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 355.214% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 860.589% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 134.998% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 15454.68% |
| Apollomics, Inc. | -27.39 Million USD | 504.709% |
| Amarin Corporation plc | -191.04 Million USD | 158.035% |
| Mesoblast Limited | 55.96 Million USD | -98.113% |
| Turnstone Biologics Corp. | -14.58 Million USD | 860.217% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 538.36% |
| Synaptogenix, Inc. | -28.66 Million USD | 486.826% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 11945.085% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | -127.51% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 12960.621% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 1625.857% |
| Exelixis, Inc. | -73.05 Million USD | 251.773% |
| Better Therapeutics, Inc. | -860 Thousand USD | 12991.86% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 561.708% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 145.933% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -14962.508% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 1590.562% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -8741.308% |
| Gritstone bio, Inc. | 39.49 Million USD | -180.755% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 231.83% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 4312.162% |
| Avid Bioservices, Inc. | 169.72 Million USD | 34.678% |
| Insmed Incorporated | 721.62 Million USD | 84.636% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 1312.819% |
| MediWound Ltd. | -5.32 Million USD | 2183.239% |
| OmniAb, Inc. | 9.2 Million USD | -1104.716% |
| Alector, Inc. | -35.63 Million USD | 411.109% |
| Seres Therapeutics, Inc. | 85.97 Million USD | -28.962% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 2349.797% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -737.45% |
| Zai Lab Limited | -775 Million USD | 114.306% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 67.444% |
| Aura Biosciences, Inc. | -21.52 Million USD | 615.075% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 234.42% |
| Immunic, Inc. | -45.34 Million USD | 344.53% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 157.382% |
| Veracyte, Inc. | -203.82 Million USD | 154.395% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 82.63% |
| FibroGen, Inc. | 56.76 Million USD | -95.307% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -1145.031% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 4021.712% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 5455.138% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 97.585% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 3418.468% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 166.804% |
| TG Therapeutics, Inc. | 17.86 Million USD | -520.703% |
| Galecto, Inc. | -21.21 Million USD | 622.577% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 566.134% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 92.936% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 553.048% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 1063.5% |
| XBiotech Inc. | -200.02 Million USD | 155.429% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 231.83% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -2348.542% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 414.409% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 243.581% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -1848.164% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 165.059% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 220.023% |
| Vaxxinity, Inc. | 10.13 Million USD | -994.256% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 84.942% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 1129.668% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 268.097% |
| NexImmune, Inc. | -3.13 Million USD | 3638.055% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 3311.135% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 833.682% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 509.114% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 1335.175% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 89098.595% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 373.267% |
| Ainos, Inc. | 4.07 Million USD | -2618.783% |
| Pluri Inc. | 22.82 Million USD | -385.654% |
| Prothena Corporation plc | -608.34 Million USD | 118.225% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 193.359% |
| Celularity Inc. | 65.19 Million USD | -70.072% |
| Rallybio Corporation | -24.1 Million USD | 560.003% |
| Cue Biopharma, Inc. | -33.81 Million USD | 427.833% |
| MeiraGTx Holdings plc | -40.3 Million USD | 375.098% |
| Omeros Corporation | 331.17 Million USD | 66.522% |
| Humacyte, Inc. | -22.48 Million USD | 593.062% |
| Immunocore Holdings plc | -358.59 Million USD | 130.918% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 551.15% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 458.791% |
| Blueprint Medicines Corporation | 702.83 Million USD | 84.225% |
| CalciMedica, Inc. | -5.53 Million USD | 2104.882% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 158.904% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 1185.471% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 376.919% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 433.414% |
| Pulmatrix, Inc. | -10.41 Million USD | 1164.318% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 1954.944% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 390.677% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 199.522% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 284.956% |
| Cytokinetics, Incorporated | 642.37 Million USD | 82.741% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 2004.001% |
| Nutriband Inc. | -251.65 Thousand USD | 44155.997% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 424.951% |
| Vor Biopharma Inc. | 4.3 Million USD | -2478.372% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 101.837% |
| Evogene Ltd. | -19.63 Million USD | 664.684% |
| ProKidney Corp. | -56.23 Million USD | 297.151% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 327.79% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 1300.257% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 91.871% |
| CorMedix Inc. | -43.05 Million USD | 357.523% |
| BioLineRx Ltd. | 7.33 Million USD | -1411.314% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 503.677% |
| Galectin Therapeutics Inc. | 46.14 Million USD | -140.254% |
| Atai Life Sciences N.V. | -28.55 Million USD | 488.227% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -4870.57% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 585.931% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -525.148% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 247.681% |
| MediciNova, Inc. | -50.78 Million USD | 318.319% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 240.689% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 492965.081% |
| GeoVax Labs, Inc. | -6.45 Million USD | 1818.225% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 155.485% |
| Biomea Fusion, Inc. | -166.57 Million USD | 166.561% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 161.947% |
| Mereo BioPharma Group plc | -51.46 Million USD | 315.411% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 216.897% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 137.742% |
| Absci Corporation | -72.59 Million USD | 252.718% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -2328.165% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 147.292% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 217.683% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 215.856% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 383.751% |
| Allakos Inc. | -24.97 Million USD | 543.924% |
| Imunon, Inc. | -4.21 Million USD | 2731.084% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 852.069% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 181.883% |
| BioAtla, Inc. | -109.01 Million USD | 201.705% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -14962.508% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 11907.242% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -826.542% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 622.898% |
| XOMA Corporation | -29 Million USD | 482.31% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 769.505% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 1329.703% |
| aTyr Pharma, Inc. | -7.44 Million USD | 1588.388% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 188.955% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 153.261% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 235.573% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 219.52% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 13004.104% |
| Akari Therapeutics, Plc | -3.84 Million USD | 2983.485% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -6731.64% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 91.971% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 9431.431% |
| UroGen Pharma Ltd. | 4.39 Million USD | -2424.937% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 2.301% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -153967.424% |
| Orgenesis Inc. | 21.78 Million USD | -408.952% |
| Entera Bio Ltd. | -10.62 Million USD | 1143.09% |
| GH Research PLC | -78.07 Million USD | 242.001% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 597.443% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 515.882% |
| Xencor, Inc. | 29.64 Million USD | -274.005% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 5728.456% |
| Replimune Group, Inc. | 1.41 Million USD | -7751.983% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 45370.061% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 187.702% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 9431.431% |
| Portage Biotech Inc. | -4.98 Million USD | 2325.858% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 492965.081% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 267.675% |
| OncoCyte Corporation | -6.56 Million USD | 1789.319% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -12254.401% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 2533.685% |
| Purple Biotech Ltd. | -14.13 Million USD | 884.199% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 566.703% |
| scPharmaceuticals Inc. | -6.54 Million USD | 1793.965% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 764.204% |
| HilleVax, Inc. | -165.48 Million USD | 166.997% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 4468.4% |
| Tharimmune, Inc. | -10.93 Million USD | 1113.868% |
| Genprex, Inc. | -6.73 Million USD | 1745.534% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 130.062% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 225.333% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 8013.633% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 3442.533% |
| OKYO Pharma Limited | -826.84 Thousand USD | 13508.752% |
| Savara Inc. | 153 Thousand USD | -72364.052% |
| Curis, Inc. | -23.88 Million USD | 564.144% |
| Daré Bioscience, Inc. | -5.15 Million USD | 2249.514% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 14387.15% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 1885.921% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -9256.118% |
| BeiGene, Ltd. | -2.25 Billion USD | 104.921% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -798.57% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 118.229% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 159.74% |
| Erasca, Inc. | -37.21 Million USD | 397.91% |
| bluebird bio, Inc. | 108.57 Million USD | -2.118% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 8708.634% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 70.727% |
| DBV Technologies S.A. | -126.98 Million USD | 187.309% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 8708.634% |
| Moderna, Inc. | -2.9 Billion USD | 103.814% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 1171.001% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 1120.151% |
| Molecular Templates, Inc. | 707 Thousand USD | -15581.754% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 453.416% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 68.013% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 235.105% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 220.866% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 443.549% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 422.522% |
| MacroGenics, Inc. | -66.98 Million USD | 265.515% |
| RenovoRx, Inc. | -1.17 Million USD | 9551.833% |
| Adicet Bio, Inc. | -138.78 Million USD | 179.885% |
| Prime Medicine, Inc. | -27.94 Million USD | 496.8% |
| Aditxt, Inc. | 18.12 Million USD | -511.835% |
| Adagene Inc. | -87.62 Million USD | 226.524% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 2761.671% |
| Quantum-Si incorporated | -118.55 Million USD | 193.516% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | -207.929% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 1583.372% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 328.556% |
| SciSparc Ltd. | -2.06 Million USD | 5469.007% |
| Vericel Corporation | 1.27 Million USD | -8582.067% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 1024.556% |
| Minerva Neurosciences, Inc. | 41 Million USD | -170.387% |
| Generation Bio Co. | 31.44 Million USD | -252.55% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 163.223% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 458.536% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 4.909% |
| Invivyd, Inc. | -198.47 Million USD | 155.861% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 222.82% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 4724.037% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 256.618% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 1724.469% |
| 2seventy bio, Inc. | 181.71 Million USD | 38.987% |
| ADMA Biologics, Inc. | 90.06 Million USD | -23.099% |
| Clene Inc. | 3.34 Million USD | -3219.461% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 1320.672% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 615.411% |
| GeoVax Labs, Inc. | -6.45 Million USD | 1818.225% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 132.218% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 526.428% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 37.596% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 2809.72% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -2116.513% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 2228.432% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 185.086% |
| Evaxion Biotech A/S | 5.28 Million USD | -1997.092% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 198.492% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 184.458% |
| Trevena, Inc. | 2.25 Million USD | -4810.097% |
| Surrozen, Inc. | -32.66 Million USD | 439.426% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 315.24% |
| Cingulate Inc. | 3.08 Million USD | -3496.542% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 3874.94% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -1442.646% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 1293.276% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 239.77% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 184.343% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 205.048% |
| Clearmind Medicine Inc. | -3.94 Million USD | 2912.077% |
| Kronos Bio, Inc. | -36.05 Million USD | 407.511% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -1078.34% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -7503.59% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 304.346% |
| Statera Biopharma, Inc. | 14.41 Million USD | -669.054% |
| ImmunityBio, Inc. | 618.22 Million USD | 82.066% |
| Korro Bio, Inc. | -132.94 Million USD | 183.397% |
| Kineta, Inc. | -4.54 Million USD | 2541.533% |
| BioVie Inc. | -17.73 Million USD | 725.241% |
| Codexis, Inc. | -43.27 Million USD | 356.222% |
| Celularity Inc. | 65.19 Million USD | -70.072% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 3598.58% |
| Celcuity Inc. | 6.78 Million USD | -1534.405% |
| Virax Biolabs Group Limited | -3.36 Million USD | 3394.854% |
| Cibus, Inc. | -8.07 Million USD | 1472.493% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 2721.66% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -2326.039% |
| IN8bio, Inc. | -16.38 Million USD | 776.49% |
| Kodiak Sciences Inc. | -103.87 Million USD | 206.734% |
| Annexon, Inc. | -193.75 Million USD | 157.222% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -307872.222% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 733.579% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 3255.992% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 89.484% |
| Eyenovia, Inc. | 1.25 Million USD | -8708.28% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -312.08% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 3518.748% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 433.474% |
| Arcellx, Inc. | -296.95 Million USD | 137.335% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 668.389% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 288.314% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 634.906% |
| Moolec Science SA | 117.61 Thousand USD | -94164.386% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 388.731% |
| Geron Corporation | 14.76 Million USD | -651.101% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 392.394% |
| Royalty Pharma plc | 5.65 Billion USD | 98.041% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 178.397% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 1686.254% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 2167.367% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 178.782% |
| Humacyte, Inc. | -22.48 Million USD | 593.062% |
| Structure Therapeutics Inc. | -124.33 Million USD | 189.168% |
| 89bio, Inc. | -289.05 Million USD | 138.356% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 539.228% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 6318.172% |
| Genelux Corporation | -6.89 Million USD | 1707.044% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 456.966% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | -32.621% |
| Notable Labs, Ltd. | -9.77 Million USD | 1234.104% |
| Liquidia Corporation | -80.17 Million USD | 238.283% |
| Mustang Bio, Inc. | -3.73 Million USD | 3067.612% |
| Immunovant, Inc. | -635.22 Million USD | 117.454% |
| Quantum-Si incorporated | -118.55 Million USD | 193.516% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 731.234% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 2776.08% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -1281.213% |
| Acasti Pharma Inc. | -23 Million USD | 581.939% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 3392.618% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 782.303% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 180.492% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 3657.674% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 598.696% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 697.07% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 165.496% |
| PepGen Inc. | -60.67 Million USD | 282.743% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 582.547% |
| United Therapeutics Corporation | -507.7 Million USD | 121.838% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 679.682% |
| Solid Biosciences Inc. | -47.75 Million USD | 332.188% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 12960.621% |
| Immuneering Corporation | -54.94 Million USD | 301.791% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 2737.571% |
| Silo Pharma, Inc. | -3.52 Million USD | 3245.866% |
| Belite Bio, Inc | -87.27 Million USD | 227.041% |
| XOMA Corporation | -29 Million USD | 482.31% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 256.824% |
| Bionomics Limited | 227 Million USD | 51.161% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 195.346% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 4477.023% |
| uniQure N.V. | -102.95 Million USD | 207.692% |
| Cassava Sciences, Inc. | -121.13 Million USD | 191.525% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 2761.671% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | -170.738% |
| Forte Biosciences, Inc. | -11.96 Million USD | 1026.929% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 3683.156% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -104494.34% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 3518.748% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -1145.031% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 1595.011% |
| Altimmune, Inc. | -134.48 Million USD | 182.439% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 44.023% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 4477.023% |
| Compugen Ltd. | -12.9 Million USD | 959.191% |
| Peak Bio, Inc. | 10.34 Million USD | -972.227% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 39276.678% |
| Benitec Biopharma Inc. | -50.58 Million USD | 319.189% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 206.26% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -464.368% |
| Zura Bio Limited | -99.8 Million USD | 211.086% |
| PolyPid Ltd. | 6.17 Million USD | -1696.921% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | -49.582% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -464.368% |
| Instil Bio, Inc. | 75.35 Million USD | -47.124% |
| argenx SE | -2.02 Billion USD | 105.465% |
| Immunome, Inc. | -97.02 Million USD | 214.265% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 592.865% |
| Verona Pharma plc | -220.44 Million USD | 150.294% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 254.538% |
| Shattuck Labs, Inc. | -121.42 Million USD | 191.308% |
| CervoMed Inc. | -7.79 Million USD | 1522.715% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 159.769% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 2635.33% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 184.158% |
| Moolec Science SA | 117.61 Thousand USD | -94164.386% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 4945.765% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -597.367% |
| AnaptysBio, Inc. | -18.15 Million USD | 710.82% |
| Design Therapeutics, Inc. | -18.15 Million USD | 710.854% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 257.528% |
| NeurAxis, Inc. | 145.7 Thousand USD | -75994.715% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -887.09% |
| Lumos Pharma, Inc. | -28.49 Million USD | 489.113% |
| Achilles Therapeutics plc | -126.92 Million USD | 187.351% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 254.538% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 17007.874% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 633.7% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -7503.59% |
| Nutriband Inc. | -251.65 Thousand USD | 44155.997% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 941.774% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 1590.188% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 67.41% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -367.116% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 124.777% |
| Palisade Bio, Inc. | -12.06 Million USD | 1019.091% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 179.017% |
| Beam Therapeutics Inc. | -262.72 Million USD | 142.201% |
| Neurogene Inc. | -131.95 Million USD | 184.021% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -408.205% |
| AEON Biopharma, Inc. | -4.88 Million USD | 2371.926% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 129.394% |
| Sesen Bio, Inc. | -112.55 Million USD | 198.505% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 211.025% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 4822.307% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 384.093% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 233.126% |
| Athira Pharma, Inc. | -88.99 Million USD | 224.574% |
| Vaccinex, Inc. | -1.28 Million USD | 8707.919% |
| HCW Biologics Inc. | 2.85 Million USD | -3781.084% |
| XOMA Corporation | -29 Million USD | 482.31% |
| Nektar Therapeutics | 210.24 Million USD | 47.265% |
| Arvinas, Inc. | -313.8 Million USD | 135.331% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -6731.64% |
| Merus N.V. | -192.88 Million USD | 157.48% |
| Omega Therapeutics, Inc. | 59.98 Million USD | -84.83% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 1698.011% |
| Rezolute, Inc. | -68.16 Million USD | 262.642% |
| Clene Inc. | 3.34 Million USD | -3219.461% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 940.752% |
| BeyondSpring Inc. | -13.75 Million USD | 906.034% |
| Synlogic, Inc. | -6.68 Million USD | 1758.489% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -9676.896% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 1411.295% |
| Peak Bio, Inc. | 10.34 Million USD | -972.227% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 234.518% |
| Krystal Biotech, Inc. | -350.23 Million USD | 131.656% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 10.679% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 165.605% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 3611.718% |
| MannKind Corporation | 143.89 Million USD | 22.953% |
| Ikena Oncology, Inc. | -109.15 Million USD | 201.57% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 1564.404% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 434.955% |
| Gossamer Bio, Inc. | 180.35 Million USD | 38.527% |
| CohBar, Inc. | -5.93 Million USD | 1969.415% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 472.697% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -2328.165% |
| Legend Biotech Corporation | -949.39 Million USD | 111.678% |
| Mural Oncology plc | -255.84 Million USD | 143.335% |
| Biora Therapeutics, Inc. | 32.21 Million USD | -244.156% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 2453.607% |
| Disc Medicine, Inc. | -358.28 Million USD | 130.945% |
| Champions Oncology, Inc. | 4.81 Million USD | -2204.032% |
| REGENXBIO Inc. | 54.76 Million USD | -102.436% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 41329.868% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 173.412% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 1330.248% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 237.414% |
| Vaxart, Inc. | -8.24 Million USD | 1445.346% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 320.945% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 187.185% |
| Cellectis S.A. | -43.85 Million USD | 352.81% |
| Longeveron Inc. | -2.9 Million USD | 3912.586% |
| Repare Therapeutics Inc. | -107.85 Million USD | 202.793% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 88.551% |
| Inozyme Pharma, Inc. | 12 Million USD | -823.609% |
| Revolution Medicines, Inc. | -608.2 Million USD | 118.229% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 9113.821% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 141.819% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 173.878% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 808.57% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 15082.432% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 101.159% |
| Denali Therapeutics Inc. | -74.86 Million USD | 248.093% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 1024.556% |
| Veru Inc. | 4.77 Million USD | -2219.471% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 1085.862% |
| Cingulate Inc. | 3.08 Million USD | -3496.542% |
| Passage Bio, Inc. | 4.58 Million USD | -2318.103% |
| Context Therapeutics Inc. | -14.44 Million USD | 867.276% |
| Exicure, Inc. | 5.84 Million USD | -1795.538% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 148.126% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 380.187% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -606.583% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 288.487% |
| Nuvalent, Inc. | -335.38 Million USD | 133.057% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -6292.63% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 248.855% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 1347.132% |
| OmniAb, Inc. | 9.2 Million USD | -1104.716% |
| Anew Medical, Inc. | 1.43 Million USD | -7639.805% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -576.79% |
| Lipocine Inc. | -4.75 Million USD | 2431.851% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 200.949% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -627.923% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 318.855% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -345.404% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 1749.606% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 268.426% |
| Ocugen, Inc. | -32.52 Million USD | 440.918% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 229.559% |
| Q32 Bio Inc. | -37.94 Million USD | 392.163% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 17754.459% |
| Alumis Inc. Common Stock | -13.52 Million USD | 919.499% |
| Equillium, Inc. | -22.39 Million USD | 595.132% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 533.628% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 439.813% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 44820.973% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 17.287% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -3366.854% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -33656.443% |
| Dominari Holdings Inc. | 195 Thousand USD | -56756.41% |
| Edesa Biotech, Inc. | -5.26 Million USD | 2205.029% |
| vTv Therapeutics Inc. | -8.91 Million USD | 1343.355% |
| Bio-Techne Corporation | 267.74 Million USD | 58.592% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 784.003% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 193.883% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 1419.41% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 976.373% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 145.231% |
| Nkarta, Inc. | 57.29 Million USD | -93.494% |
| BioCardia, Inc. | 212 Thousand USD | -52197.17% |
| Iterum Therapeutics plc | 13.43 Million USD | -725.048% |